万赛维可以治什么呢？

(Valcyte) is an oral anti-cytomegalovirus infection drug developed by the Swiss company Roche. Its main ingredient is valganciclovir hydrochloride. It is currently used to treat induction therapy of CMV retinitis, maintenance therapy of CMV retinitis and prevention of CMV infection in transplant patients.

Meanwhile, on August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Valcyte for the treatment of adult kidney transplant patients at high risk of cytomegalovirus (CMV) disease.

Roche announced on August 31, 2009 that the U.S. Food and Drug Administration (FDA) has approved Valcyte (trade name: Valcyte; generic name: valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) infection in pediatric kidney and heart transplant patients aged 4 months to 16 years. Such children are considered to be a high-risk group for CMV infection.

The safety and efficacy of the treatment were verified in two different trials: The antiviral effect of Vancevir was clinically confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with Valcyte, and the U.S. Food and Drug Administration (FDA) approved the increased use of Valcyte in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with Valcyte reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients treated for 100 days) to 16.8% (for patients treated for 200 days) one year after receiving a kidney transplant) (p <0.0001).1.2 The overall safety profile of Valcyte did not change when prophylaxis was extended in high-risk renal transplant patients.